1. Home
  2. STAA vs PTGX Comparison

STAA vs PTGX Comparison

Compare STAA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$20.64

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$142.25

Market Cap

9.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
PTGX
Founded
1982
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
9.3B
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
STAA
PTGX
Price
$20.64
$142.25
Analyst Decision
Buy
Strong Buy
Analyst Count
9
13
Target Price
$22.81
★ $108.23
AVG Volume (30 Days)
★ 803.8K
526.9K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
0.26
★ 2.35
Revenue
★ $239,442,000.00
N/A
Revenue This Year
$30.82
$874.25
Revenue Next Year
$8.41
N/A
P/E Ratio
$73.38
★ $58.44
Revenue Growth
N/A
★ N/A
52 Week Low
$15.59
$62.24
52 Week High
$35.87
$160.81

Technical Indicators

Market Signals
Indicator
STAA
PTGX
Relative Strength Index (RSI) 40.21 46.76
Support Level $19.82 $141.95
Resistance Level $26.21 $151.24
Average True Range (ATR) 1.05 5.11
MACD -0.22 -0.89
Stochastic Oscillator 30.25 48.37

Price Performance

Historical Comparison
STAA
PTGX

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: